|
 
 |
| REVIEW ARTICLE |
|
| Year : 2016 | Volume
: 6
| Issue : 3 | Page : 108-118 |
|
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications–phenotypes and genetic predispositions
Mayumi Ueta
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kamigyoku, Kyoto, Japan
| Date of Web Publication | 10-Aug-2016 |
Correspondence Address:
Mayumi Ueta
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji, Kawaramachi, Kamigyoku, Kyoto 602-0841
Japan
 Source of Support: None, Conflict of Interest: None  | 10 |
DOI: 10.1016/j.tjo.2016.06.001
Stevens–Johnson syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the skin and mucosa, such as the ocular surface, oral cavity, and genitals. In patients with extensive skin detachment and a poor prognosis, the condition is called toxic epidermal necrolysis (TEN). Severe ocular complications (SOCs) appear in some–but not all–SJS/TEN patients who are diagnosed by dermatologists, and cold medicines including multi-ingredient cold medications and nonsteroidal anti-inflammatory drugs are the main causative drugs particularly for SJS/TEN with SOCs and all SJS and TEN. In this review, we focus on the genetic predisposition of cold medicine-related SJS/TEN (CM-SJS/TEN) with SOCs. CM-SJS/ TEN with SOCs was strongly associated with HLA-A*02:06 and significantly associated with HLA-B*44:03 in Japanese individuals, significantly associated with HLA-B*44:03 in Indian and Brazilian individuals, and associated with HLA-A*02:06 in Korean individuals. In the first genome-wide association study (GWAS), we found an association between the prostaglandin E receptor 3 (PTGER3) gene and SJS/ TEN with SOCs. In this study, we focused on CM-SJS/TEN with SOCs and found that the association of CM-SJS/TEN with SOCs became stronger than all SJS/TEN with SOCs. In the second GWAS, we found an association between the IKZFi gene and CM-SJS/TEN with SOCs not only in Japanese, but also in Korean and Indian populations. Moreover, we found that TSHZ2 gene single nucleotide polymorphisms (SNPs) also showed especially low p values in the Japanese population; however, this association was not found in the Korean population. Furthermore, we investigated the interaction between susceptibility genes, and found multiplicative interactions of HLA-A*02:06 and TLR3 SNPs and additive interactions of HLA-A*02:06 and PTGER3 SNPs.
How to cite this article:
Ueta M. Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications–phenotypes and genetic predispositions. Taiwan J Ophthalmol 2016;6:108-18 |
How to cite this URL:
Ueta M. Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications–phenotypes and genetic predispositions. Taiwan J Ophthalmol [serial online] 2016 [cited 2023 Mar 25];6:108-18. Available from: https://www.e-tjo.org/text.asp?2016/6/3/108/204302 |
| 1. Stevens–Johnson syndrome/toxic epidermal necrolysis in ophthalmology | |  |
Stevens–Johnson syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the skin and mucosa, such as the ocular surface, oral cavity, and genitals. In patients with extensive skin detachment and a poor prognosis, the condition is called toxic epidermal necrolysis (TEN). [Table 1] shows the diagnostic criteria for SJS and TEN in Japan.[1] Adefinite diagnosis of SJS requires mucosal lesions, whereas a definite diagnosis of TEN does not. Thus, SJS/TEN with mucosal lesions consists of SJS and a part of TEN. Moreover, not all cases of SJS/TEN with mucosal lesions have severe ocular lesions such as severe conjunctivitis with pseudomembrane and ocular surface epithelial defects in the acute stage [Figure 1]. [Figure 2] shows a case of severe conjunctivitis with pseudomem-brane and ocular surface epithelial defects in the acute stage. It is reported that about 40% of SJS/TEN cases had severe ocular complications (SOCs) with pseudomembrane and ocular surface epithelial defects.[1] | Figure 1. Ophthalmologists often report both SJS and TEN with severe ocular complications as SJS. SJS=StevenseJohnson syndrome; TEN=toxic epidermalnecrolysis.Note. From Ueta M. Genetic predisposition to StevenseJohnson syndrome with severe ocular surface complications. Cornea. 2015;34(Suppl. 11):S158eS165. Reproduced with permission.
Click here to view |
 | Figure 2: Severe conjunctivitis with pseudomembrane and ocular surface epithelial defects in the acute stage of StevenseJohnson syndrome (SJS). Reproduced from Ueta with permission from Medical-Aoi Publications, Inc.
Click here to view |
 | Table 1: Diagnostic criteria for StevenseJohnson syndrome and toxic epidermal necrolysis by Japanese Ministry of Health, Labour, and Welfare (2005).
Click here to view |
Furthermore, dermatologists see SJS/TEN patients only in their acute stage, whereas ophthalmologists encounter such patients not only in the acute stage but also in the chronic stage. Therefore, for ophthalmologists, it is not easy to render a differential diagnosis of SJS or TEN when patients present in the chronic stage because the vesiculobullous skin lesions expressed in the acute stage have healed by the chronic stage.[2] Diagnosis of SJS/TEN in ophthalmology was based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and involvement of at least two mucosal sites including the ocular surface.[3],[4],[5],[6],[7],[8],[9],[10],[11],[12],[13],[14] SJS/TEN patients with SOC in the acute stage often experience severe ocular sequelae, such as vision loss and very severe dry eye for which these patients would not have been able to lead a normal life.[15] [Figure 3] shows severe ocular sequelae such as very severe dry eye, trichiasis, symbrepharon, scarring of lid conjunctiva, and conjunctival invasion of the cornea in the chronic stage. We defined patients with SOCs in the acute stage as those who manifested pseudomembranes and epithelial defects on the ocular surface (cornea and/or conjunctiva),[16] and in the chronic stage as patients with ocular sequelae such as severe dry eye, trichiasis, symblepharon, and conjunctival invasion into the cornea.[15] Thus, ophthalmologists tend to report both SJS and TEN with SOCs as “SJS” in a broad sense.[2] | Figure 3: Severe ocular sequelae such as very severe dry eye, trichiasis, symbrepharon, scarring of lid conjunctiva and conjunctival invasion of cornea in the chronic stage of Stevens–Johnson syndrome (SJS). Reproduced from Ueta with permission from Medical-Aoi Publications, Inc.
Click here to view |
To summarize, SOCs appear in some–but not all–SJS/TEN patients who are diagnosed by dermatologists.
| 2. Causative drug and human leukocyte antigen analysis | | |
SJS/TENs are rare with an annual incidence rate of 1–6 cases/1 million persons,[1],[17],[18] but SJS/TEN carry high mortality rates of 3% for SJS and 27% for TEN.[19] Moreover, they often associated with inciting drugs.[3],[4],[5],[10],[18],[20],[21],[22] It was reported that allopurinol and anticonvulsants such as carbamazepine are the main inciting drugs for SJS/TEN[23]; however, we[2],[3],[4],[5],[10] and others[20],[22] found that cold medicines including multi-ingredient cold medications and nonsteroidal anti-inflammatory drugs (NSAIDs) are also major causative drugs for SJS/TEN.
Furthermore, the association between human leukocyte antigen (HLA) genotypes and drug-induced severe cutaneous adverse reactions (SCARs) including SJS/TEN has been reported. Carbamazepine-induced SJS/TEN exhibited a very strong association with the HIA-B*15:02 allele [case n = 44, control (tolerant) n = 101, odds ratio (OR) = 2504, pcorrected = 3.1 × 10−27in Taiwanese Han Chinese patients.[24] The HLA-A*31:01 allele was also reported to be strongly associated with carbamazepine-induced SCAR including SJS/TEN and drug-induced hypersensitivity syndrome (DIHS) in Japanese [case n = 77, control (tolerant) n = 420, OR = 9.5, p = 1.1 × 10[25][[16]] and European individuals [case n = 145, control (normal) n = 257, OR = 15.0, p = 3.5 × 10−8],[26] suggesting that different ethnic groups may have the different risk factors for carbamazepine-induced SCARs. Allopurinol, a uric acid-lowering drug, could also induce SCAR including SJS, TEN, and DIHS, and allopurinol-induced SCARs were strongly associated with HLA-B* 58:01 in Han Chinese [case n = 51, control (tolerant) n = 135, OR = 580, pcorrected = 4.7 × 10−24],[27] Caucasian [case n = 27, control (normal) n = 1822, OR = 80, pcorrected <10−6],[28] and Japanese patients (case n =36, control (normal) n = 986, OR = 62.8, p = 5.4 × 10−12),[29] suggesting that different ethnic groups may share the same risk factors for allopurinol-induced SCARs.
We have also reported that cold medicine-related SJS/TEN (CM-SJS/TEN) with SOCs was strongly associated with HLA-A*02:06 [case n = 151, control (normal) n = 639, OR = 5.6, p = 2.7 × 10[20]] and significantly associated with HLA-B*44:03 in Japanese individuals [case n = 151, control (normal) n = 639, OR = 2.0, p = 1.3 ×10−3, and these HLA genotypes were irrelevant to CM-SJS/TEN without SOCs.[3] Thus, genetic predisposition such as HLA genotype might be different between SJS/TEN with and without SOCs.[3] Moreover, HLA-A*02:06 and HLA-B*44:03 are not associated with cold medicine unrelated (other medicine related) SJS/TEN with SOCs,[3] suggesting that genetic predisposition, such as HLA genotype, might be different depending on their causative drugs.[3],[5],[30],[31]
We also reported that CM-SJS/TEN with SOCs was significantly associated with HLA-B*44:03 in Indian [case n = 20, control (normal) n = 55, OR = 12.3,p = 1.1 × 10−5and Brazilian [especially Brazilian Caucasians; case n = 15, control (normal) n = 62, OR = 6.2, p = 3.7 × 10−3 individuals, and that HLA-A*02:06 was associated with CM-SJS/TEN with SOC in Korean individuals [case n = 31, control (normal) n = 90, OR = 3.0, p = 0.018].[4]
We have likewise reported that cold medicines including multi-ingredient cold medications and NSAIDs were the main causative drugs for SJS/TEN with SOCs in all SJS and TEN.[1],[2],[3],[5],[10],[31] About 80% of our SJS/TEN with SOC patients have developed SJS/TEN within several days after receiving treatment for common cold.[2],[10]
Interestingly, allopurinol might induce SJS/TEN without SOCs,[30] and not all cases of carbamazepine-induced SJS/TEN have SOCs.[2]
In summary, genetic predisposition, such as HLA genotype, might be different depending on the causative drugs and their phenotype, for example, with and without SOCs [Figure 4].[2],[3],[5],[31] | Figure 4: Associations between HLA type and the main causative drugs of SJS/TEN. HLA = human leukocyte antigen; NSAIDs = nonsteroidal anti-inflammatory drugs; SJS = StevenseJohnson syndrome; TEN = toxic epidermal necrolysis. Note. From“IKZF1, a new susceptibility gene for cold medicine-related StevenseJohnson syndrome/toxic epidermal necrolysis with severe mucosal involvement,” by M. Ueta, H. Sawai, C. Sotozono C, et al., 2015, J Allergy Clin Immunol, 135, p. 1538e1545. Copyright 2015, Mosby. Reproduced with permission.
Click here to view |
| 3. Genome wide association study | | |
3.1. PTGER3: first genome-wide association study
We previously reported that a genome-wide association study (GWAS) using the Affymetrix GeneChip Mapping 500K Array Set (Affymetrix, Santa Clara, Calif) showed an association between prostaglandin E receptor 3 (PTGER3) gene and SJS/TEN with SOCs.[10] Moreover, we analyzed a total of 38 single nucleotide polymorphisms (SNPs) of the PTGER3 gene using DigiTag2 assay[32],[33] and found 20 SNPs associated with SJS/TEN with SOCs [Figure 5].[34] Theprotein of PTGER3 gene is EP3. EP3 is one of the four receptors (EP1, EP2, EP3 and EP4) of prostaglandin E2 (PGE2).[35] | Figure 5: 20 SNPs of PTGER3 associated with SJS/TEN with severe ocular complication. PTGER3 = prostaglandin E receptor 3; SJS = StevenseJohnson syndrome; SNP = single nucleotide polymorphism; TEN = toxic epidermal necrolysis. Note. From “Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes,” by M. Ueta, G. Tamiya, K. Tokunaga, et al., 2012, J Allergy Clin Immunol, 129, p. 1413e1416. Copyright 2012, Mosby. Reproduced with permission.
Click here to view |
Cold medicine such as NSAIDs (e.g., ibuprofen and loxoprofen) and cold medicine ingredients (e.g., acetaminophen) have the suppressive effect in the production of prostanoid, including PGE [Figure 6].[35] | Figure 6: Cold medicine such as nonsteroidal anti-inflammatory drugs (NSAIDs) and cold medicine ingredients have the suppressive effect of the production of prostanoid, including PGE2.
Click here to view |
It was reported that PGE2 acts at EP3 in the airway epithelium and negatively regulates inflammation in the mouse asthma model.[36] We also reported that EP3 negatively regulated the inflammation of ocular surface in the mouse allergy conjunctivitis model[37] and skin in the mouse contact dermatitis model.[38] Because PGE2 acts at EP3 and negatively regulates mucocuta-neous inflammation,[36],[37],[38] we suggest that the suppression of PGE2 production by cold medicine might contribute to the onset and pathogenesis of CM-SJS/TEN with SOCs.[2],[10] Therefore, we turned to CM-SJS/TEN with SOCs. When we focused on CM-SJS/TEN with SOCs, the association with PTGER3 gene became stronger than that in total SJS/TEN with SOCs; seven of 18 SNPs already reported to be associated with SJS/TEN were significantly associated with CM-SJS/TEN with SOCs after Bonferroni correc-tion.[14] PTGER3 SNP rs1327464 (G vs. A) was most significantly associated with CM-SJS/TEN with SOCs; the OR for the major allele was 0.232 (p = 7.92 × 10−10)[14]. [Figure 7] shows the p values of the 18 SNPs in the dominant models; PTGER3 SNP rs1327464 (GG vs. GA + AA); p = 1.90 × 10−8,OR = 0.223.[14] | Figure 7: PTGER3 SNPs associated with CM-SJS/TEN with SOCs. PTGER3 SNP rs1327464 was most significantly associated with CM-SJS/TEN with SOCs
Click here to view |
We also previously reported that EP3 protein levels are much lower in the conjunctival epithelium of patients with SJS/TEN with SOCs than control individuals such as conjunctival chalasis patients and chemical burn patients [Figure 8].[39] Thus, EP3 expression might be downregulated in the ocular surface of the SJS/TEN with SOCs patients. | Figure 8: Downregulation of EP3 in the conjunctival epithelium of SJS/TEN with severe ocular complications. EP3 (brown stain) is strongly downregulated in the conjunctival epithelium of SJS compared with chemical burns. Controls consisted of isotype control antibodies instead of anti-EP3 antibodies. SJS = StevenseJohnson syndrome; TEN = toxic epidermal necrolysis. Note. From “Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders,” by M. Ueta, C. Sotozono, N. Yokoi, T. Inatomi, S. Kinoshita, 2011, PLoS One, 6, p. e25209. Copyright 2011, Public Library of Science. Reproduced with permission. M. Ueta / Taiwan Journal of Ophthalmology 6 (2016) 108e11112 8
Click here to view |
Furthermore, because patients with CM-SJS/TEN with SOCs have developed this condition by taking cold medicines after having a common cold as a result of some viral or mycoplasma infections, we assume that not only cold medicine, but also some microbial infectious such as virus or mycoplasma, might be important and necessary to trigger the onset of SJS/TEN with SOCs.[2],[31]
3.2. IKZF1: second GWAS
In the second GWAS, we focused on CM-SJS/TEN with SOCs, and performed a GWAS of Japanese 117 cases and 691 controls using the Affymetrix AXIOM Genome-Wide ASI 1 Array (Affymetrix, Santa Clara, Calif).[5] The Manhattan plot of the GWAS indicated that the HLA-A region showed the strongest association with susceptibility to CM-SJS/TEN with SOCs [Figure 9],[5] which was consistent with findings from our previous studies.[3],[11],[12] | Figure 9: Manhattan plot of a genome-wide association study using the Affymetrix AXIOM Genome-Wide ASI 1 Array. HLA = human leukocyte antigen. Note. From “IKZF1, a new susceptibility gene for cold medicine-related StevenseJohnson syndrome/toxic epidermal necrolysis with severe mucosal involvement,” by M. Ueta, H. Sawai, C. Sotozono C, et al., 2015, J Allergy Clin Immunol, 135, p. 1538e1545. Copyright 2015, Mosby. Reproduced with permission.
Click here to view |
Outside of the HLA region, there were 60 SNPs with p < 10−3 (in the allele frequency, dominant model, or recessive model) in the GWAS.[5] Of the 60 SNPs, 47 were p < 10−4, and 11 of these 47 were p < 10−5.[5] Among the 11 SNPs of eight genes that were p < 10−5, IKZF1 showed especially low p values [rs897693: (C vs. T) OR = 4.3, p = 1.2 × 10−7; (CC + CT vs. TT), OR = 5.0, p = 2.1 × 10−8].[5]
Moreover, we genotyped the SNPs of the IKZF1 gene with all Japanese samples (149 SJS, 877 controls) with 16 additional Japanese cases, Korean samples (31 SJS and 90 controls), Indian samples (20 CM-SJS/TEN with SOCs and 56 controls), and Brazilian samples (39 CM-SJS/TEN with SOCs and 135 controls), and then found that a meta-analysis from the Japanese, Korean, Indian, and Brazilian samples showed a significant genome-wide association between CM-SJS/TEN with SOCs and IKZF1 [rs4917014 (G vs. T), OR = 0.5, p = 8.5 × 10−11.[5] These findings show that IKZF1 may be a universal marker for susceptibility to CM-SJS/TEN with SOCs.[5] Furthermore, we have performed a functional analysis for SNPs of the IKZF1 gene and found that the Ik2/Ik1 (both are splicing isoforms) ratio may be influenced by IKZF1 SNPs that are significantly associated with susceptibility to CM-SJS/TEN with SOCs.[5] To elucidate the role of IKZF1 in the pathogenesis of CM-SJS/TEN with SOCs, we are going to do further investigations.
3.3. TSHZ2: second GWAS
Among the 11 SNPs of eight genes that were p < 10−5 in the second GWAS, TSHZ2 also showed especially low p values [rs4809905: (Avs. G), OR = 0.4, p = 5.6 × 10−7; (AA + AG vs. GG), OR = 0.3, p = 1.5 × 10−7].[5] Furthermore, we have examined a total of 17 SNPs of the near region of TSHZ2 gene using 101 CM-SJS/TEN cases and 200 control samples, and found that seven SNPs (rs4811338, rs1555278, rs2092954, rs4371408, rs6021911, rs4809905, and rs6096940) showed a significant genome-wide association with CM-SJS/TEN with SOCs [Table 2]. However, these SNPs were not associated with CM-SJS/TEN with SOCs in the Korean population (data not shown). TSHZ2 might be a susceptibility gene for CM-SJS/TEN with SOCs in the Japanese population.
| 4. Interaction between susceptibility genes | | |
4.1. HLA-A*02:06 and TLR3
SNPs have been widely used as genetic markers for identifying human disease susceptibility genes for the past decade. Moreover, it has recently become apparent that gene–gene interactions are meaningful in addition to major single-locus effects.[34] We previously reported that, in addition, HLA-A*02:06,[3],[11],[12] PTGER3,[10],[34] and IKZF1,[5] TLR3[9],[34] SNPs showed significant associations with SJS/TEN with SOCs, although the expression of TLR3 protein on the ocular surface was not different between SJS/TEN and controls such as conjunctival chalasis and chemical burn [Figure 10].[34] | Figure 10. TLR3 expression in the conjunctival epithelium of SJS/TEN with severe ocular complications. The expression of TLR3 protein (brown stain) on the ocular surface was not different between SJS/TEN and controls such as conjunctival chalasis and chemical burn. Controls consisted of isotype control antibodies instead of anti-EP3 antibodies. SJS = StevenseJohnson syndrome; TEN = toxic epidermal necrolysis. Note. From “Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes,” by M. Ueta, G. Tamiya, K. Tokunaga, et al., 2012, J Allergy Clin Immunol, 129, p. 1413e1416. Copyright 2012, Mosby. Reproduced with permission.
Click here to view |
When we focused on CM-SJS/TEN with SOCs, five of the seven SNPs, which were significantly associated with SJS/TEN with SOCs in our previous report,[13],[34] were still associated with CM-SJS/TEN with SOCs [Table 3]. | Table 3: Association with TLR3 SNPs in CM-SJS/TEN with SOC in Japanese individuals.
Click here to view |
We previously also reported that HLA-A*02:06 with TLR3 SNPs exerted more than additive effects in SJS/TEN with SOCs.[13] When we focused on CM-SJS/TEN with SOCs, more than additive effects of HLA-A*02:06 with TLR3 SNPs in CM-SJS/TEN with SOCs were still observed. HLA-A*02:06 and TLR3 SNP rs3775296T/T or TLR3 SNP rs5743312T/T exerted more than additive effects (p < 0.00005, OR = 37.7, Woolf’s correction or p < 0.00005, OR = 37.5, Woolf’s correction): 10 of 133 patients (7.5%) manifested both HLA-A*02:06 and TLR3 rs3775296T/T SNP or TLR3 rs5743312T/T SNP, whereas none of the controls did [Table 4]. There was a strong linkage disequilibrium (LD) between rs.3775296 and rs.5743312. Moreover,HLA-A*02:06 and TLR3 SNP rs3775290A/A exerted additive effects (p < 0.00005, OR = 9.9): 16 of 133 patients (12.0%) manifested both HLA-A*02:06 and TLR3 rs3775290A/A SNP, whereas only three of 220 controls (1.4%) did [Table 4].  | Table 4: Interaction between HLA-A*02:06 and TLR3 SNPs in CM-SJS/TEN with SOCs.
Click here to view |
By interaction analysis, HLA-A*02:06 and TLR3 SNP rs3775296T/ T, which were in strong LD with TLR3 SNP rs5743312T/T, manifested more than additive effects; therefore, the multiplicative interactions of HLA-A and TLR3 gene might be required for the onsetof CM-SJS/TEN with SOCs.
HLA-A is a component of HLA Class I, which resides on the surface of all nucleated cells and alerts the immune system that the cell may be infected by a virus, thereby targeting the cell for destruction, and TLR3 recognizes viral double-stranded RNA.[40]
As the onset of SJS/TEN was associated not only with the administration of drugs but also with putative microbial infection, multiplicative interactions of HLA-A and TLR3 gene might contribute to the characteristic and pathogenic immune response to the microbial infection.
4.2. HLA-A*02:06 and PTGER3
Next, we looked for interactive effects between these seven SNPs of the PTGER3 gene and HLA-A*02:06 in CM-SJS/TEN with SOCs, because the PTGER3 SNPs were significantly associated with the patients.[14] We found an interaction with additive effects between HLA-A*02:06 and the high-risk genotypes PTGER3 rs1327464 GA or AA (OR = 10.8, p = 2.56 × 10−7; Table 5).[14] In the Japanese population, although PTGER3 rs1327464 GA/AA alone showed OR = 4.48 and p = 1.90 × 10−8, and HLA-A*02:06 alone showed OR = 5.46 and p = 1.39 × 10−11, the combination of PTGER3 rs1327464 GA/AA and HLA-A*02:06 could show a higher OR (OR = 10.8, p = 2.56 × 10−7) than each allele alone. | Table 5: Interaction between HLA-A*02:06 and PTGER3 rs1327464 GA/AA among Japanese individuals.
Click here to view |
Moreover, we found that even in Korean populations, there was an additive effect between the SNPs of the PTGER3 gene and HLA-A*02:06 [Table 6].[14] In the Korean population, the combination of PTGER3 rs1327464 GA/AA and HLA-A*02:06 could show a higher OR (OR = 14.2, p = 5.58 × 10−6) than each allele alone, although PTGER3 rs1327464 GA/AA alone showed OR = 4.07 and p = 0.00101, and HLA-A*02:06 alone showed OR = 2.50 and p = 0.0412. | Table 6: Interaction between HLA-A*02:06 and PTGER3 rs1327464 GA/AA among Korean individuals.
Click here to view |
Thus, the interaction between HLA-A*02:06 and PTGER3 SNP might strongly contribute to the onset of CM-SJS/TEN with SOCs.
| 5. Application strategy in future | | |
Because CM-SJS/TEN is a rare condition that probably has a complex genetic background, it is reasonable to posit multiplicative interactions of genes such as HLA-A and TLR3,[13] and HLA-A and PTGER3.[14]
Notably, after removing samples with both HLA-A*02:06 and TLR3 SNP rs3775296 T/T, the additive effect between HLA-A*02:06 and PTGER3 rs1327464 GA/AA persisted in CM-SJS/TEN with SOCs, suggesting that the interactions are independent of each other.[14]
These findings might show that the combinations of the two CM-SJS/TEN with SOCs associated polymorphisms, such as HLA-A*02:06 and TLR3 SNP and HLA-A*02:06 and PTGER3 SNP, could give improvements for a genetic testing compared with using only one susceptibility gene.[14]
Based on all of our previous observations, we suggest that in addition to microbial infections and cold medicines, the combination of multiple gene polymorphisms and their interactions contribute strongly to the onset of CM-SJS/TEN with SOCs.[14]
Acknowledgments
This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government (BioBank Japan Project), and by the JSPS Core-to-Core Program, A. Advanced Research Networks, and also partly supported by grants-in-aids for scientific research from the Japanese Ministry of Health, Labor and Welfare, and a research grant from the Kyoto Foundation for the Promotion of Medical Science and the Intramural Research Fund of Kyoto Prefectural University of Medicine.
Conflicts of interest: The author has no conflicts of interest to declare.
| References | | |
| 1. | Sotozono C, Ueta M, Nakatani E, et al. Predictive factors associated with acute ocular involvement in Stevens–Johnson syndrome and toxic epidermal nec-rolysis. Am J Ophthalmol. 2015;160, 228–237 e2.  |
| 2. | Ueta M, Kinoshita S. Ocular surface inflammation is regulated by innate immunity. Prog Retin Eye Res. 2012;31:551–575. |
| 3. | Ueta M, Kaniwa N, Sotozono C, et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens–Johnson syndrome with severe mucosal involvement. Sci Rep. 2014;4:4862. http:// dx.doi.org/10.1038/srep04862. |
| 4. | Ueta M, Kannabiran C, Wakamatsu TH, et al. Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens–Johnson syndrome with severe ocular surface complications. Sci Rep. 2014;4:5981. http://dx.doi.org/10.1038/srep05981. |
| 5. | Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens–Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy ClinImmunol. 2015;135,1538–1545 e17. |
| 6. | Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of IL4R polymorphisms with Stevens–Johnson syndrome. JAllergy Clin Immunol. 2007;120:1457–1459. |
| 7. | Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens–Johnson syndrome accompanied by ocular surface complications. Invest Ophthalmol Vis Sci. 2008;49:1809–1813. |
| 8. | Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of Fas Ligand gene polymorphism with Stevens–Johnson syndrome. Br J Ophthalmol. 2008;92:989–991. |
| 9. | Ueta M, Sotozono C, Inatomi T, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens–Johnson syndrome. Br J Ophthalmol. 2007;91:962–965. |
| 10. | Ueta M, Sotozono C, Nakano M, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens–Johnson syndrome identified by means of a genome-wide association study. JAllergy Clin Immunol. 2010;126, 1218–1225 e10. |
| 11. | Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A*0206 and Stevens–Johnson syndrome in the Japanese. Am J Ophthalmol. 2007;143:367–368. |
| 12. | Ueta M, Tokunaga K, Sotozono C, Inatomi T, Yabe T, Matsushita M, et al. HLA class I and II gene polymorphisms in Stevens–Johnson syndrome with ocular complications in Japanese. Mol Vis. 2008;14:550–555. |
| 13. | Ueta M, Tokunaga K, Sotozono C, et al. HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens–Johnson syndrome with severe ocular surface complications. PLoS One. 2012;7:e43650. |
| 14. | Ueta M, Tokunaga K, Sotozono C, et al. HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens–Johnson syndrome with severe ocular complications. Hum Genome Var. 2015;2:15023. |
| 15. | Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens–Johnson syndrome. Ophthalmology. 2007;114:1294–1302. |
| 16. | Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009;116:685–690. |
| 17. | Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43–47. |
| 18. | Yetiv JZ, Bianchine JR, Owen Jr JA. Etiologic factors of the Stevens–Johnson syndrome. South Med J. 1980;73:599–602. |
| 19. | Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Steven-s–Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669–1676. |
| 20. | Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333: 1600–1607. |
| 21. | Ueta M. Ethnic differences in the association between human leukocyte antigen and Stevens–Johnson syndrome. Eur Ophthalmic Rev. 2009;3:15–18. |
| 22. | Yamane Y, Aihara M, Ikezawa Z. Analysis ofStevens–Johnsonsyndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419–425. |
| 23. | Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128: 35–44. |
| 24. | Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428:486. |
| 25. | Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20:1034–1041. |
| 26. | McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364: 1134–1143. |
| 27. | Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–4139. |
| 28. | Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99–107. |
| 29. | Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13:60–69. |
| 30. | Lee HS, Ueta M, Kim MK, et al. Analysis of ocular manifestation and genetic association of allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in South Korea. Cornea. 2016;35:199–204. |
| 31. | Ueta M. Genetic predisposition to Stevens–Johnson syndrome with severe ocular surface complications. Cornea. 2015;34:S158–S165. |
| 32. | Nishida N, Mawatari Y, Sageshima M, Tokunaga K. Highly parallel and short-acting amplification with locus-specific primers to detect single nucleotide polymorphisms by the DigiTag2 assay. PLoS One. 2012;7:e29967. |
| 33. | Nishida N, Tanabe T, Takasu M, Suyama A, Tokunaga K. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem. 2007;364:78–85. |
| 34. | Ueta M, Tamiya G, Tokunaga K, et al. Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes. J Allergy Clin Immunol. 2012;129, 1413–1416 e11. |
| 35. | Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. Sci World J. 2007;7:1329–1347. |
| 36. | Kunikata T, Yamane H, Segi E, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol. 2005;6:524–531. |
| 37. | Ueta M, Matsuoka T, Narumiya S, Kinoshita S. Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis. J Allergy Clin Immunol. 2009;123:466–471. |
| 38. | Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prosta-glandin E(2)–EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. 2009;124, 809–818 e2. |
| 39. | Ueta M, Sotozono C, Yokoi N, Inatomi T, Kinoshita S. Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders. PLoS One. 2011;6:e25209. |
| 40. | Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24–32. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]
| This article has been cited by | | 1 |
Susceptibility Genes and HLA for Cold Medicine-Related SJS/TEN with SOC |
|
| Mayumi Ueta | | Frontiers in Genetics. 2022; 13 | | [Pubmed] | [DOI] | | | 2 |
Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications |
|
| Mayumi Ueta | | Frontiers in Medicine. 2021; 8 | | [Pubmed] | [DOI] | | | 3 |
Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications |
|
| Mayumi Ueta | | Frontiers in Medicine. 2021; 8 | | [Pubmed] | [DOI] | | | 4 |
Clinical Aspects of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications in Taiwan |
|
| David Hui-Kang Ma,Tsung-Ying Tsai,Li-Yen Pan,Shin-Yi Chen,Ching-Hsi Hsiao,Lung-Kun Yeh,Hsin-Yuan Tan,Chun-Wei Lu,Chun-Bing Chen,Wen-Hung Chung | | Frontiers in Medicine. 2021; 8 | | [Pubmed] | [DOI] | | | 5 |
Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese |
|
| Kevin Sheng-Kai Ma, Wen Hung Chung, Yi-Jen Hsueh, Shin-Yi Chen, Katsushi Tokunaga, Shigeru Kinoshita, David H K Ma, Mayumi Ueta | | British Journal of Ophthalmology. 2021; : bjophthalm | | [Pubmed] | [DOI] | | | 6 |
HLA genotypes and cold medicine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis |
|
| Wimonchat Tangamornsuksan,Sirikan Chanprasert,Phenphechaya Nadee,Saowalak Rungruang,Natnaree Meesilsat,Mayumi Ueta,Manupat Lohitnavy | | Scientific Reports. 2020; 10(1) | | [Pubmed] | [DOI] | | | 7 |
Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept |
|
| Petra Borilova Linhartova,Daniela Gachova,Bretislav Lipovy | | The Journal of Dermatology. 2020; | | [Pubmed] | [DOI] | | | 8 |
Multi-Step Grading System for Evaluation of Chronic Ocular Sequelae in Patients with Stevens-Johnson Syndrome |
|
| Namrata Sharma,Renu Venugopal,Prafulla K. Maharana,Manthan Chaniyara,Tushar Agarwal,Neelam Pushker,Ravinder Mohan Pandey,Sushil Sangwan,Seema Sen,Seema Kashyap,Arundhati Sharma,Neena Khanna,Rasik B. Vajpayee | | American Journal of Ophthalmology. 2019; | | [Pubmed] | [DOI] | | | 9 |
Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease |
|
| Chihiro Udagawa,Hidehito Horinouchi,Kouya Shiraishi,Takashi Kohno,Takuji Okusaka,Hideki Ueno,Kenji Tamura,Yuichiro Ohe,Hitoshi Zembutsu,Rania Mohamed Labib | | PLOS ONE. 2019; 14(10): e0223371 | | [Pubmed] | [DOI] | | | 10 |
Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications |
|
| Mayumi Ueta | | Investigative Opthalmology & Visual Science. 2018; 59(14): DES183 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for